Suramin, a drug for the treatment of trypanosomiasis, reduces the prothrombotic and metastatic phenotypes of colorectal cancer cells by inhibiting hepsin.

doi:10.1016/j.biopha.2023.115814

Article

Suramin, a drug for the treatment of trypanosomiasis, reduces the prothrombotic and metastatic phenotypes of colorectal cancer cells by inhibiting hepsin.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie - 1 Dec 2023

Zaragoza-Huesca David, Rodenas Maria Carmen, Peñas-Martínez Julia, Pardo-Sánchez Irene, Peña-García Jorge, Espín Salvador, Ricote Guillermo, Nieto Andrés, García-Molina Francisco, Vicente Vicente, Lozano Maria Luisa, Carmona-Bayonas Alberto, Mulero Victoriano, Pérez-Sánchez Horacio, Martínez-Martínez Irene

Abstract excerpt

Recently, our group identified serine-protease hepsin from primary tumor as a biomarker of metastasis and thrombosis in patients with localized colorectal cancer. We described hepsin promotes invasion and thrombin generation of colorectal cancer cells in vitro and in vivo and identified venetoclax as a hepsin inhibitor that suppresses these effects. Now, we aspire to identify additional hepsin inhibitors, aiming...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Caco-2 Cells

Suramin, a drug for the treatment of trypanosomiasis, reduces the prothrombotic and metastatic phenotypes of colorectal cancer cells by inhibiting hepsin.

Abstract excerpt

Topics

Related research